CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 29, 2013--
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
completion of its previously announced public offering of 15,307,000
shares of common stock at a public offering price of $19.60 per share.
In addition, the underwriters have exercised an option to purchase an
additional 1,182,893 shares at $19.60 per share to cover
over-allotments. The total gross proceeds from the offering are
approximately $323 million. Net proceeds to ARIAD are approximately $310
million after deducting underwriting discounts and commissions and
estimated offering expenses.
J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies &
Company, Inc. acted as joint book-running managers and underwriters for
the offering. BMO Capital Markets, Leerink Swann LLC, RBC Capital
Markets, LLC and UBS Investment Bank acted as co-managers for the
A shelf registration statement on Form S-3 relating to the public
offering of the shares of common stock described above was filed with
the Securities and Exchange Commission (the “SEC”) and is effective. A
final prospectus supplement relating to the offering has been filed with
the SEC. Copies of the final prospectus supplement and accompanying
prospectus may be obtained from the offices of J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 (Telephone number 866-803-9204), the offices of Cowen
and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717 (Telephone number 631-274-2806), or the
offices of Jefferies & Company, Inc., Equity Syndicate Prospectus
Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by
telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the
discovery, development and commercialization of medicines to transform
the lives of cancer patients. For more information about ARIAD, visit
the company’s website at www.ariad.com.
Source: ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.
Liza Heapes, 617-621-2315